Mucosis has developed a novel vaccine technology, the Mimopath® technology. This technology enables us to development of novel and more efficacious vaccines with improved patient convenience.
Based on the Mimopath® technology, Mucosis is developing intranasal vaccines to prevent respiratory syncytial virus, influenza, shigella/etec and pneumococcal disease. Mucosis is interested in partnering with companies for its vaccine discovery and development pipeline.
Mucosis is also licensing the Mimopath® vaccine technology to vaccine companies. This will boost the use of our vaccine technology in multiple vaccine programs throughout the industry, and will generate licensing revenues.
Department of Virology, University of Utrecht (The Netherlands): Mucosis collaborates with the Department of Virology to develop a vaccine to prevent and treat diseases caused by respiratory syncytial virus.
PATH (USA): Mucosis collaborates with PATH on programs targeted at the use of Mucosis’ proprietary vaccine technology for prevention of Shigella/ETEC diseases.
The Laboratory for Pediatric Infectious Diseases, Radboud University Nijmegen Medical Centre (The Netherlands): Mucosis collaborates with the Laboratory for Pediatric Infectious Diseases to develop a vaccine to prevent and treat diseases caused by pneumococcal bacteria.
Center for Vaccine Development, University Maryland Baltimore (USA): Mucosis collaborates with the Center for Vaccine Development at the University of Maryland in Baltimore on a program targeted at the use of Mucosis’ proprietary vaccine technology for pediatric applications.